Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris (Nasdaq: VTRS) reported third-quarter 2025 results and updated full-year guidance on Nov 6, 2025.

Key Q3 metrics: Total revenues $3.76B (flat YoY), Adjusted EBITDA $1.155B (down 10% YoY), Adjusted EPS $0.67 (down 11% YoY), U.S. GAAP net loss $(128)M. The company generated $744.9M operating cash and $658.1M free cash flow in Q3.

Business updates include the acquisition of Aculys Pharma (pitolisant and Spydia rights in Japan/APAC), FDA approval of Iron Sucrose Injection, NDA submission for a low-dose estrogen weekly patch (expect mid-2026 approval), and >$920M returned to shareholders YTD including $500M in buybacks. Guidance ranges for 2025 revenues, adjusted EBITDA and adjusted EPS were raised and narrowed.

Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared by the board on November 3, 2025. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 24, 2025. This provides a concrete cash return timetable for VTRS shareholders.

Locus Biosciences announced a research collaboration with Viatris (NASDAQ: VTRS) on October 28, 2025 to develop precision engineered bacteriophage therapeutics for serious ophthalmic bacterial infections.

The collaboration will apply Locus’s platform—predictive AI, high-throughput robotics, and synthetic biology—to create bacteriophage cocktails aimed at selectively eliminating eye-pathogenic bacteria while sparing beneficial species. The program targets infections complicated by rising antibiotic resistance and seeks to advance phage-based alternatives or complements to traditional antibiotics.

Viatris (Nasdaq: VTRS) completed the acquisition of Aculys Pharma, acquiring exclusive Japan development and commercialization rights to pitolisant and exclusive Japan and select Asia‑Pacific rights to Spydia Nasal Spray.

Viatris said pitolisant showed strong Phase 3 results in Japanese patients and is on track for an MHLW marketing application for narcolepsy and OSAS-related daytime sleepiness by end of 2025. Spydia received approval in Japan in June 2025 for status epilepticus. Transaction consideration includes an upfront payment, contingent regulatory/commercial milestone payments, and royalties on net sales.

Viatris (Nasdaq: VTRS) will participate in two investor events in November 2025. The company will appear in a fireside chat at the UBS Global Healthcare Conference on November 11, 2025 at 8:45 a.m. ET, and in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 11:30 a.m. GMT / 6:30 a.m. ET. Investors and the public can listen live and access archived sessions at investor.viatris.com for a limited time after each event.

Viatris (Nasdaq: VTRS) was named to Forbes' World's Best Employers 2025, marking the company's fifth consecutive year on the list. The ranking, compiled by Forbes and Statista, surveyed more than 300,000 participants across 50 countries and included 900 companies.

Viatris highlighted workplace priorities such as wellbeing, inclusivity, learning and development, and noted prior recognitions including TIME's World's Most Sustainable Companies 2024 and Forbes' World's Top Companies for Women 2024. More information is available on Viatris' careers site and its 2024 Sustainability Report.

Viatris Inc. (NASDAQ: VTRS) has scheduled its third quarter 2025 financial results announcement for Thursday, November 6, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly performance.

Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay will be available on the company's website following the presentation.

Viatris (NASDAQ: VTRS) has appointed Andrew Enrietti as Chief Administrative and Transformation Officer in a newly created position. Enrietti, who previously served as Chief People Officer, will oversee multiple key functions including Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate.

With over 20 years of career experience, including 10 years at Viatris and its legacy companies, Enrietti brings expertise in financial services, M&A, talent strategy, and organizational effectiveness. The appointment aims to centralize leadership of the company's digital, cultural, and structural transformation initiatives to accelerate strategic evolution.

Viatris (NASDAQ:VTRS) has received FDA approval for the first generic version of Iron Sucrose Injection, USP, used to treat iron deficiency anemia in chronic kidney disease patients. The product will be available in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.

The company secured Competitive Generic Therapy (CGT) designation for two strengths, granting 180 days of exclusivity. The reference drug, Venofer®, had annual U.S. sales of $515M as of June 2025. This approval demonstrates Viatris' capabilities in developing complex generic medicines and strengthens its injectable pipeline, which includes other iron replacement products like ferric carboxymaltose injection.